Capital Advisors Inc’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $272K | Hold |
4,990
| – | – | ﹤0.01% | 319 |
|
|
2026
Q1 | $237K | Sell |
4,990
-44
| -0.9% | -$2.32K | ﹤0.01% | 325 |
|
|
2025
Q4 | $264K | Sell |
5,034
-105
| -2% | -$6.29K | ﹤0.01% | 286 |
|
|
2025
Q3 | $333K | Sell |
5,139
-1,853
| -27% | -$106K | 0.01% | 246 |
|
|
2025
Q2 | $340K | Sell |
6,992
-300,506
| -98% | -$11.6M | 0.01% | 244 |
|
|
2025
Q1 | $10.5M | Sell |
307,498
-2,772
| -0.9% | -$118K | 0.21% | 86 |
|
|
2024
Q4 | $12.2M | Buy |
310,270
+9,681
| +3% | +$457K | 0.24% | 90 |
|
|
2024
Q3 | $14.1M | Buy |
300,589
+22,583
| +8% | +$1.15M | 0.28% | 86 |
|
|
2024
Q2 | $15M | Buy |
278,006
+14,020
| +5% | +$811K | 0.31% | 86 |
|
|
2024
Q1 | $18M | Buy |
263,986
+8,721
| +3% | +$624K | 0.39% | 82 |
|
|
2023
Q4 | $16M | Buy |
255,265
+23,340
| +10% | +$1.29M | 0.36% | 83 |
|
|
2023
Q3 | $10.5M | Buy |
231,925
+15,951
| +7% | +$824K | 0.28% | 84 |
|
|
2023
Q2 | $12.1M | Buy |
215,974
+50,193
| +30% | +$2.85M | 0.31% | 84 |
|
|
2023
Q1 | $7.5M | Buy |
165,781
+35,867
| +28% | +$1.74M | 0.2% | 89 |
|
|
2022
Q4 | $5.28M | Buy |
129,914
+1,552
| +1% | +$82.3K | 0.15% | 92 |
|
|
2022
Q3 | $6.94M | Buy |
128,362
+2,477
| +2% | +$180K | 0.22% | 88 |
|
|
2022
Q2 | $7.65M | Buy |
125,885
+20,903
| +20% | +$1.23M | 0.23% | 90 |
|
|
2022
Q1 | $6.59M | Buy |
104,982
+2,510
| +2% | +$158K | 0.18% | 88 |
|
|
2021
Q4 | $7.76M | Buy |
102,472
+31,800
| +45% | +$2.78M | 0.21% | 91 |
|
|
2021
Q3 | $7.91M | Buy |
70,672
+1,191
| +2% | +$150K | 0.24% | 92 |
|
|
2021
Q2 | $11.2M | Buy |
69,481
+1,724
| +3% | +$210K | 0.34% | 91 |
|
|
2021
Q1 | $8.26M | Sell |
67,757
-19,911
| -23% | -$3.01M | 0.27% | 90 |
|
|
2020
Q4 | $13.4M | Sell |
87,668
-49,232
| -36% | -$5.82M | 0.48% | 77 |
|
|
2020
Q3 | $11.4M | Buy |
136,900
+403
| +0.3% | +$35.7K | 0.46% | 77 |
|
|
2020
Q2 | $12.7M | Buy |
136,497
+2,918
| +2% | +$171K | 0.53% | 66 |
|
|
2020
Q1 | $5.67M | Buy |
133,579
+6,550
| +5% | +$338K | 0.31% | 73 |
|
|
2019
Q4 | $7.74M | Buy |
127,029
+10,872
| +9% | +$594K | 0.34% | 82 |
|
|
2019
Q3 | $5.47M | Hold |
116,157
| – | – | 0.27% | 84 |
|
|
2019
Q2 | $5.47M | Buy |
116,157
+63,678
| +121% | +$2.55M | 0.27% | 84 |
|
|
2019
Q1 | $1.88M | Sell |
52,479
-65,340
| -55% | -$2.26M | 0.2% | 86 |
|
|
2018
Q4 | $3.37M | Buy |
117,819
+10,387
| +10% | +$361K | 0.22% | 87 |
|
|
2018
Q3 | $4.76M | Buy |
107,432
+991
| +0.9% | +$51.9K | 0.28% | 87 |
|
|
2018
Q2 | $6.25M | Sell |
106,441
-42,476
| -29% | -$2.42M | 0.38% | 79 |
|
|
2018
Q1 | $6.81M | Sell |
148,917
-787
| -0.5% | -$32.5K | 0.41% | 80 |
|
|
2017
Q4 | $3.52M | Buy |
+149,704
| New | +$2.84M | 0.21% | 94 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Capital Advisors Inc's CRSP Position: Q2 2026 in Review
Capital Advisors Inc held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 4,990 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #319.
Capital Advisors Inc first reported a position in CRSP in Q4 2017 and has held it in 35 quarters since. The position peaked at $18M in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Capital Advisors Inc held 4,990 shares of CRISPR Therapeutics worth $272K as of Q2 2026.
- Capital Advisors Inc left its CRISPR Therapeutics share count unchanged in Q2 2026.
- CRISPR Therapeutics made up ﹤0.01% of Capital Advisors Inc's portfolio in Q2 2026, its #319 holding.
- Capital Advisors Inc first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Capital Advisors Inc's CRISPR Therapeutics position peaked at $18M in Q1 2024.
- 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Capital Advisors Inc's 13F filing for Q2 2026, filed 23 Jul 2026.